Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063539 | 1.00 | ADORA3 (0.40) | ADORA3TSHRMC4RADRA1AMC3R | |
| Urea SCHEMBL11380529 | 0.98 | ADORA3 (0.39) | ADORA3TSHRMC4RADRA1AMC3R | |
| Ammonia Solution, Strong SCHEMBL28836911 | 0.98 | LMNA (0.40) | ADORA3TSHRMC4RADRA1AMC3R | |
| Hydrochloric Acid SCHEMBL5672456 | 0.98 | ADORA3 (0.39) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2492969 | 0.82 | TSHR (0.48) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL5684624 | 0.80 | SMN1; SMN2 (0.40) | TSHRLMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL569230 | 0.78 | SMN1; SMN2 (0.48) | TSHRLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1452735 | 0.78 | SMN1; SMN2 (0.39) | TSHRSIRT6LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30042917 | 0.78 | SMN1; SMN2 (0.48) | TSHRLMNASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1452738 | 0.76 | LMNA (0.47) | TSHRLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108892646-A | Chloro- 2- pyrazinamide class compound of a kind of 6- containing diphenyl ether base and the preparation method and application thereof | 上海凯爱网络科技有限公司 | 2018-11-27 | — | — | CN | claimed |
| CN-106795147-A | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use | 美国安进公司 | 2017-05-31 | — | — | CN | claimed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| WO-2004058265-A1 | COMPOUND LIBRARIES OF 2,3-SUBSTITUTED PYRAZINE DERIVATIVES CAPABLE OF BINDING TO G-PROTEIN COUPLED RECEPTORS | BIOFOCUS PLC (GB) | 2004-07-15 | — | — | WO | claimed |
| EP-4739677-A1 | TRIAZOLE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739673-A1 | TRIAZOLE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739674-A1 | TRIAZOLE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20250129052-A1 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-04-24 | — | — | US | disclosed |
| WO-2025008247-A1 | TRIAZOLE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6902902-B2 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004058265-A1 | COMPOUND LIBRARIES OF 2,3-SUBSTITUTED PYRAZINE DERIVATIVES CAPABLE OF BINDING TO G-PROTEIN COUPLED RECEPTORS | BIOFOCUS PLC (GB) | 2004-07-15 | — | — | WO | disclosed |
| US-4085211-A | DIURETICS, NATRIURETICS | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129052-A1 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | API5, DDT, PIR | ADORA3 4381/4885TSHR 3155/4885MC4R 1698/4885 |
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | ADORA3 130/4885TSHR 206/4885MC4R 180/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | ADORA3 130/4885TSHR 206/4885MC4R 180/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | ADORA3 130/4885TSHR 206/4885MC4R 180/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | ADORA3 130/4885TSHR 206/4885MC4R 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.